Tofogliflozin ameliorates cardiotoxin induced skeletal muscle injury and fibrosis in obesity

Abstract Obesity impairs muscle function through effects on lipid metabolism, systemic inflammation, and insulin resistance, leading to muscle loss and reduced regeneration. Tofogliflozin (Tofo), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), exclusively inhibits SGLT2 and is used to treat hyp...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Muhammad Bilal, Nguyen Quynh Phuong, Tomonobu Kado, Jianhui Liu, Le Duc Anh, Sana Khalid, Muhammad Rahil Aslam, Memoona, Ayumi Nishimura, Yoshiko Igarashi, Yoshiyuki Watanabe, Waseem Abbas, Maki Yokoyama, Yasuhiro Onogi, Kenichi Hirabayashi, Seiji Yamamoto, Kunimasa Yagi, Marsel Lino, Isao Usui, Masaru Kato, Shiho Fujisaka, Allah Nawaz, Kazuyuki Tobe
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2025-10-01
Edice:	Scientific Reports
Témata:	Skeletal muscle Cardiotoxin-induced injury Fibro-adipogenic progenitors (FAPs) Follistatin Exercise tolerance
On-line přístup:	https://doi.org/10.1038/s41598-025-12734-9
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!